The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S24-S30 , May 2006

New Treatment Strategies for Patients with Hypertension and Insulin Resistance

  • Theodore W. Kurtz, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Theodore W. Kurtz, MD, Department of Laboratory Medicine, University of California, San Francisco, 185 Berry Street, Suite 290, San Francisco, California 94107.

References 

  1. Alberti KG , Zimmet PZ . Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation . Diabet Med . 1998;15:539–553
  2. Third report of the National Cholesterol Evaluation Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report . Circulation . 2002;106:3143–3421
  3. Balkau B , Vernay M , Mhamdi L , et al.   The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French DESIR study . Diabetes Metab . 2003;29:526–532
  4. Ford ES , Giles WH . A comparison of the prevalence of the metabolic syndrome using two proposed definitions . Diabetes Care . 2003;26:575–581
  5. Isomaa B , Almgren P , Tuomi T , et al.   Cardiovascular morbidity and mortality associated with the metabolic syndrome . Diabetes Care . 2001;24:683–689
  6. Lakka HM , Laaksonen DE , Lakka TA , et al.   The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men . JAMA . 2002;288:2709–2716
  7. Sattar N , Gaw A , Scherbakova O , et al.   Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease in the West of Scotland Coronary Prevention Study . Circulation . 2003;108:414–419
  8. Kahn R , Buse J , Ferrannini E , Stern M . The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetes Care . 2005;28:2289–2304
  9. Ames RP . A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides . Am J Cardiol . 1996;77:12b–16b
  10. Schmitz G , Stumpe KO , Herrmann W , Weidirger G . Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial . Blood Pressure . 1996;5:354–359
  11. Lithell HO . Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism . Diabetes Care . 1991;14:203–209
  12. Hansson L , Lindholm LH , Niskanen L , et al.   Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension (the Captopril Prevention Project (CAPPP) randomised trial) . Lancet . 1999;353:611–616
  13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)) . JAMA . 2002;288:2981–2997
  14. The Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients . N Engl J Med . 2000;342:145–153
  15. Dahlöf B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol) . Lancet . 2002;359:995–1003
  16. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (the VALUE randomised trial) . Lancet . 2004;363:2022–2031
  17. Pfeffer MA , Swedberg K , Granger CB , et al.   Effects of candesartan on mortality and morbidity in patients with chronic heart failure (the CHARM-Overall programme) . Lancet . 2003;362:759–766
  18. Gerstein HC , Yusuf S , Holman R , Bosch J , Pogue J  DREAM Trial Investigators . Rationale, design, and recruitment characteristics of a large, simple international trial of diabetes prevention (the DREAM trial) . Diabetologia . 2004;47:1519–1527
  19. Prisant LM . Preventing type II diabetes mellitus . J Clin Pharmacol . 2004;44:406–413
  20. Kurtz TW , Pravenec M . Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists (beyond the renin-angiotensin system) . J Hypertens . 2004;22:2253–2261
  21. Pershadsingh HA . Peroxisome proliferator-activated receptor–γ: therapeutic target for diseases beyond diabetes: Quo vadis? . Expert Opin Invest Drugs . 2004;13:215–228
  22. Savage DB , Tan GD , Acerini CL , et al.   Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor–γ . Diabetes . 2003;52:910–917
  23. Diamant M , Heine RJ . TZDs in type 2 diabetes mellitus (current clinical evidence) . Drugs . 2003;63:1373–1405
  24. Benson SC , Pershadsingh HA , Ho CI , et al.   Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity . Hypertension . 2004;43:993–1002
  25. Michel MC , Bohner H , Köster J , Schäfers R , Heemann U . Safety of telmisartan in patients with arterial hypertension (an open-label observational study) . Drug Safety . 2004;27:335–344
  26. Vitale C , Mercuro G , Castiglioni C , et al.   Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome . Cardiovasc Diabetol . 2005;4:6–13
  27. Derosa G , Ragonesi PD , Mugellini A , Ciccarelli L , Fogari R . Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism, and lipid profile in hypertensive, type 2 diabetic patients (a randomized, double-blind, placebo-controlled study) . Hypertens Res . 2004;27:457–464
  28. Miura Y , Yamamoto N , Tsunekawa S , et al.   Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes . Diabetes Care . 2005;28:757–758
  29. Yamauchi T , Kamon J , Waki Y , et al.   The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity . Nat Med . 2001;7:941–946
  30. Bassuk SS , Rifai N , Ridker PM . High-sensitivity C-reactive protein (clinical importance) . Curr Probl Cardiol . 2004;29:439–493
  31. Honjo S , Nichi Y , Wada Y , Hamamoto Y , Koshiyama H . Possible beneficial effect of telmisartan on glycemic control in diabetic subjects [letter] . Diabetes Care . 2005;28:498
  32. Pershadsingh HA , Kurtz TW . Insulin-sensitizing effects of telmisartan (implications for treating insulin-resistant hypertension and cardiovascular disease) . Diabetes Care . 2004;27:1015
  33. Derosa G , Cicero AFG , Bertone G , et al.   Comparison of the effects of telmisartan and nifedipine Gastrointestinal Therapeutic System on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension (a 12-month, randomized, double-blind study) . Clin Ther . 2004;26:1228–1236
  34. Sarafidis P , Lasaridis A , Hatzistavri L , Zebekakis P , Tziolas I . The effect of telmisartan and lekarnidipine on blood pressure and insulin resistance in hypertensive patients . Review of Clinical Pharmacology and Pharmacokinetics (international edition) . 2004;18:60–66
  35. Fogari R , Lazzari P , Zoppi A , et al.   Effect of telmisartan, losartan, and lisinopril on insulin sensitivity in hypertensive patients with and without insulin resistance . [abstract] Eur Heart J . 2004;25(suppl):78
  36. Koulouris S , Symeonides F , Vratsista E , et al.   Both ramipril and telmisartan reduce serum levels of high-sensitivity C-reactive protein without affecting low-density lipoprotein cholesterol oxidation in patients with type II diabetes mellitus . [abstract] Eur Heart J . 2003;24(suppl):145
  37. Pershadsingh H , Benson SC , Ho CI , Avery MA , Kurtz TW . Identification of PPAR gamma activators that do not promote fluid retention and edema (implications for treating insulin resistant hypertension and the metabolic syndrome) . [abstract] Hot Topics in Endocrinology . 2003;29: Proceedings of the Endocrine Society Symposium on Nuclear Receptors in Cardiovascular Disease
  38. Berger JP , Petro AE , Macnaul KL , et al.   Distinct properties and advantages of a novel peroxisome proliferator-activated protein (gamma) selective modulator . Mol Endocrinol . 2003;17:662–676
  39. Zanchi A , Chiolero A , Maillard M , Nussberger J , Brunner HR , Burnier M . Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men . J Clin Endocrinol Metab . 2004;89:1140–1145
  40. PROactive Study Investigators. Results of the PROspective PioglitAzone Clinical Trial in MicroVascular Events. Presented at: 41st Annual Meeting of the European Association for the Study of Diabetes; September 12, 2005; Athens, Greece. Available at: www.proactive-results.com. Accessed February 22, 2006.
  41. Takeda K , Ichiki T , Tokonou T , et al.   Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells . Circulation . 2000;102:1834–1839
  42. Goetze S , Xi XP , Graf K , Kleck E , Hseuh W , Law RE . Troglitazone inhibits angiotensin-II induced extracellular signal-related kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells . FEBS Lett . 1999;452:277–282
  43. The ONTARGET/TRANSCEND Investigators . Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials) . Am Heart J . 2004;148:52–61

PII: S0002-9343(06)00102-1

doi: 10.1016/j.amjmed.2006.01.011

The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S24-S30 , May 2006

Article Tools

* Image Usage & Resolution